MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative mAb therapeutics for the treatment of cancer. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation, antibody-based technology platforms, which have applicability across broad therapeutic domains. MacroGenics leverages its fully-integrated biologics capabilities that span discovery, protein engineering, animal modeling, and manufacturing to enable cost-efficient, flexible development of its proprietary as well as partner pipeline programs. In addition to manufacturing antibody-based products and product candidates in its Rockville, Maryland, commercial-scale facility for their own needs, the company also provides outsourced contract development and manufacturing services.